drugset / Trial / NCT06986031

PKB171 Against Placebo in Couples With Asthenozoospermia Who Wish to Conceive

NCT06986031

Phase 2 Terminated 60 enrolled Prokrea BCN, S.L.
RandomizedParallel-groupTriple-blindTreatment

Summary

The test medication Gel PKB171 is a vaginal gel that has not yet been licensed by the regulatory authorities. However, the active substance pentoxifylline has been available as tablets for decades and is used to increase peripheral blood flow in patients with circulation problems. Additionally, pentoxifylline is used to treat sperm samples in artificial insemination and test tube fertilisation to increase the mobility of sperm. A first trial performed in Spain, 30 women were treated with Gel PKB171 for up to three times. Gel PKB171 was generally well tolerated and the most common side effects were local reactions like vaginal discharge and itching. The aim of this clinical trial is to test if treatment with Gel PKB171 increases pregnancy rate in couples with reduced mobility of sperm (so-called asthenozoospermia). Additionally, the safety and local tolerability of Gel PKB171 was further investigated.

Timeline

Start
2017-05-08
Primary completion
2019-01-23
Completion
2019-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 150 mg Other
Subject Pentoxifylline Small molecule 200 mg Other

Indications